Article name: Empagliflozin in Patients with Chronic Kidney Disease
This article was published in the New England Journal of Medicine in 2023. It is a randomized controlled trial which compared the use of an SGLT-2 inhibitor (empaglifozin) against placebo. The endpoint was progression of chronic kidney disease (CKD) or cardiovascular death.
In the empaglifozin group, after 2 years, 13.1% of the group reached the endpoint. In the placebo group, 16.9% reached the endpoint (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P<0.001). The results were consistent amongst various subgroups including diabetics and non diabetics.